The downregulation of SPRY2 has been shown in chronic lymphocytic leukemia, non-small cell lung cancer, hepatocellular carcinoma, breast cancer, and prostate cancers [26], highlighting its tumor suppressor function. Here, SPRY2 is linked to prostate carcinoma.